Concert Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 0.021 million compared to USD 32.02 million a year ago. Net loss was USD 23.55 million compared to net income of USD 5.43 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to basic earnings per share from continuing operations of USD 0.16 a year ago. Diluted loss per share from continuing operations was USD 0.59 compared to diluted earnings per share from continuing operations of USD 0.16 a year ago.
For the six months, revenue was USD 0.022 million compared to USD 32.02 million a year ago. Net loss was USD 61.28 million compared to USD 17.24 million a year ago. Basic loss per share from continuing operations was USD 1.59 compared to USD 0.51 a year ago. Diluted loss per share from continuing operations was USD 1.59 compared to USD 0.51 a year ago.